Cargando…

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe

BACKGROUND: The aim of this study was to review and compare types of reimbursement recommendations for orphan drugs issued by eight European health technology assessment (HTA) agencies and the reimbursement status of these drugs in the corresponding countries. Separate calculations were also perform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawalec, Paweł, Sagan, Anna, Pilc, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012088/ https://www.ncbi.nlm.nih.gov/pubmed/27600717 http://dx.doi.org/10.1186/s13023-016-0501-4

Ejemplares similares

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Reimbursement of orphan drugs in Belgium: what (else) matters?
por: Picavet, Eline, et al.
Publicado: (2014)

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
por: van den Brink, Rinke
Publicado: (2014)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
por: Adkins, Elizabeth M, et al.
Publicado: (2017)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

A systematic review of moral reasons on orphan drug reimbursement
por: Zimmermann, Bettina M., et al.
Publicado: (2021)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kryst, Joanna, et al.
Publicado: (2015)

Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland
por: Holko, Przemysław, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2012)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2016)

Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges
por: Daubner-Bendes, Rita, et al.
Publicado: (2021)

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014)

Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
por: Lee, Jong Hyuk
Publicado: (2021)

Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis
por: Moćko, Paweł, et al.
Publicado: (2016)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

Health-Related Quality of Life Impairment and Indirect Cost of Crohn’s Disease: A Self-Report Study in Poland
por: Holko, Przemysław, et al.
Publicado: (2016)

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Kawalec, Paweł, et al.
Publicado: (2014)

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Nevirapine-Based Regimens in HIV-Infected Antiretroviral-Naive Patients: Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kawalec, Paweł, et al.
Publicado: (2013)

Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2018)

Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2017)

The Potential of Scopolamine as an Antidepressant in Major Depressive Disorder: A Systematic Review of Randomized Controlled Trials
por: Moćko, Paweł, et al.
Publicado: (2023)

A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries
por: Czech, Marcin, et al.
Publicado: (2020)

An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
por: Ward, Leanne Marie, et al.
Publicado: (2022)

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2021)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
por: de Andrés-Nogales, Fernando, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gbv5aacksfgrq8lph7e4v2aavo